BioReference Laboratories, Elmwood Park, NJ, an OPKO Health company, will accept an indefinite delivery indefinite quantity contract award to provide commercial surge capacity testing for covid-19 emergency response to the Centers for Disease Control and Prevention (CDC). Under the contract with the CDC, BioReference will perform antibody testing to determine covid-19 seroprevalence and will provide results with key demographic information and analysis in collaboration with the CDC. The agreement’s period of performance began July 20, 2020, and is ongoing through November 19, 2020. “Working with the CDC underscores the importance of public, private partnership to achieve a worthwhile covid-19 response,” says Jon R. Cohen, MD, executive chairman of BioReference Laboratories. “Many studies suggest that the majority of the public has not been infected with covid-19, but multiple factors limit these findings. Together with the leading public health authority, we are leveraging extensive depth and breadth of testing expertise to increase overall understanding of the disease burden of the virus.” For more information, visit BioReference Laboratories.
September 1, 2020
February 14, 2017